Board of Directors

Naveed Siddiqi, M.D., is a Partner at Novo Ventures. He brings more than 20 years of experience in life science venture investments and investment banking.

Most recently, he was Partner at Andera Partners, a Paris based venture capital and growth equity firm with over Î2 billion under management, focusing on life science investing.  Prior to that, he worked for Nomura Phase4 Ventures, Nomura International, EFG Corporate Finance, KPMG and as a medical doctor in the UK’s National Health Service. In his prior firms, Dr. Siddiqi served on several life science company boards in both Europe and the U.S. 

Dr. Siddiqi obtained his M.D. from Guy’s and St. Thomas’s Hospital Medical School (now King’s College London). Later, he also qualified as a chartered accountant from the Institute of Chartered Accountants England & Wales.

Dr. Luca Santarelli is the Chief Executive Officer, co-founder and board member of VectivBio. Dr. Santarelli has more than 20 years of experience in academic and industrial R&D, having led drug programs in the areas of neuroscience, rare diseases, ophthalmology, metabolic and G.I., spanning the value chain from discovery research to commercialization. Most recently, Dr. Santarelli served as Chief Executive Officer and co-founder of Therachon AG. Therachon was focused on the discovery and development of therapeutics for rare pediatric conditions, and was acquired by Pfizer, Inc., in 2019 for $810 million.

Prior to Therachon, he spent 12 years at Roche, most recently serving as the Senior Vice President and Head of Neuroscience, Ophthalmology and Rare Diseases, as well as Small Molecule Research at Roche in Switzerland. In this capacity, he advanced over 20 NMEs to the clinic and various NMEs to registration studies including ocrelizumab in Multiple Sclerosis, gantenerumab in Alzheimer’s disease, balovaptan in Autism, risdiplam in Spinal Muscular Atrophy and faricimab in Diabetic Macular Edema and Age-related Macular Degeneration. During this period, he also catalyzed the creation of Synosia and Clementia, two companies built from Roche’s asset spin-offs, and led the company to multiple in-licensing deals.

Previously, he was a faculty at Columbia University and a co-founder of BrainCells Inc., a company focused on the discovery of novel antidepressants that are able to stimulate the growth of new neurons, with Nobel laureate Eric Kandel, Rene Hen and Fred Gage.

Dr. Santarelli completed his M.D. and Psychiatry Residency at the University of Turin, Italy, and a postdoctoral fellowship at Columbia University, focusing on the molecular mechanisms of psychiatric disorders and adult brain stem cells. His work has been published in high impact journals including Nature, Science, Nature Neuroscience, Archives of Neurology and JAMA Psychiatry.

Tim Anderson is a Partner and Managing Director of Cowen Healthcare Investments. He focuses on investments in biotechnology and digital medicine companies that have the potential to meaningfully address serious medical conditions. Mr. Anderson is currently a member of the Board of Directors of Cadent Therapeutics, Compass Therapeutics and VectivBio Holding. Mr. Anderson previously served as a Board Member or Observer of Precision Biosciences, Therachon and Livongo Health.

Chahra Louafi is Senior Investment Director at Bpifrance.

Prior to its acquisition by Bpifrance in 2013, she spent 12 years at CDC Entreprises leading its investments in biotherapies and rare disease funds. Before joining CDC Entreprises, she led project development and entrepreneurship in a private incubator specializing in biotechnology.

She is Chairman of Inserm Transfert Initiative and currently serves on the Boards of numerous biopharmaceutical companies including Eyevensys S.A.S., Sensorion SA, Pixium Vision SA, Gecko Biomedical SAS and ENYO Pharma SAS.

Ms. Louafi earned an M.A. in Technology and Innovation Management from Paris Dauphine University, M.A. in Corporate Finance from Paris Nanterre University and M.Sc. in Microbiology and Enzymatic Engineering from the Institut National Agronomique de Paris – Grignon.

Hans Schikan currently serves as Chair of the Board of Directors for InteRNA (Netherlands) and Complix (Belgium), in addition to serving on the boards of Dutch Pharvaris and Swedish Vicore Pharma. Furthermore, he is a member of the Top Team of the Dutch Top Sector Life Sciences & Health (Netherlands).

Previously, Hans Schikan was the CEO of Prosensa, which used RNA modulating treatments to treat rare diseases such as Duchenne muscular dystrophy. During his time at Prosensa, he oversaw the listing of the company on Nasdaq and the conclusion of an M&A deal with BioMarin for up to $840 million. Prior to that, Hans Schikan held senior positions in Global Marketing and Strategic Development at Genzyme and leadership roles at Organon. Hans Schikan received his Pharm.D. from the University of Utrecht (Netherlands). He previously served on the boards of Wilson Therapeutics (acquired by Alexion), Therachon (acquired by Pfizer), Sobi, Asceneuron and Hansa Biopharma.

Stephen Squinto, Ph.D., is a Venture Partner with OrbiMed who brings over 25 years of biotechnology industry experience.

Dr. Squinto was a co-founder of Alexion Pharmaceuticals, Inc. and recently served as its Executive Vice President and Chief Global Operations Officer. Prior to 2013, he was Alexion’s Global Head of Research and Development. From 1988 to 1992, Dr. Squinto held various positions at Regeneron Pharmaceuticals, Inc. Prior to Regeneron, he held a joint academic position at both the Tulane University and LSU Medical Schools. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work. Dr. Squinto received his B.A. in Chemistry and Ph.D. in Biochemistry and Biophysics from Loyola University of Chicago.